Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.
<h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23505456/?tool=EBI |
| _version_ | 1818337906689835008 |
|---|---|
| author | Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li |
| author_facet | Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li |
| author_sort | Jian-Hong Zhong |
| collection | DOAJ |
| description | <h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4>Methods</h4>MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated.<h4>Results</h4>Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2- and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI = 0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy.<h4>Conclusion</h4>The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed. |
| first_indexed | 2024-12-13T15:02:40Z |
| format | Article |
| id | doaj.art-d68bf9e1c45f430bac18b6bbf9b63b4b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T15:02:40Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d68bf9e1c45f430bac18b6bbf9b63b4b2022-12-21T23:41:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5808210.1371/journal.pone.0058082Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma.Jian-Hong ZhongXin-Shao MoBang-De XiangWei-Ping YuanJin-Fang JiangGui-Sheng XieLe-Qun Li<h4>Aim</h4>To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results.<h4>Methods</h4>MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated.<h4>Results</h4>Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2- and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI = 0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy.<h4>Conclusion</h4>The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23505456/?tool=EBI |
| spellingShingle | Jian-Hong Zhong Xin-Shao Mo Bang-De Xiang Wei-Ping Yuan Jin-Fang Jiang Gui-Sheng Xie Le-Qun Li Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS ONE |
| title | Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. |
| title_full | Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. |
| title_fullStr | Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. |
| title_full_unstemmed | Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. |
| title_short | Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. |
| title_sort | postoperative use of the chemopreventive vitamin k2 analog in patients with hepatocellular carcinoma |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23505456/?tool=EBI |
| work_keys_str_mv | AT jianhongzhong postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT xinshaomo postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT bangdexiang postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT weipingyuan postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT jinfangjiang postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT guishengxie postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma AT lequnli postoperativeuseofthechemopreventivevitamink2analoginpatientswithhepatocellularcarcinoma |